Bard building surgical products line through $100 mil. merger with MedChem.
This article was originally published in The Gray Sheet
Executive Summary
BARD BUILDING SURGICAL PRODUCTS LINE WITH $100 MIL. MEDCHEM MERGER, the latest deal in Bard's ongoing acquisition progrm. Bard and MedChem jointly announced on May 24 that their boards had approved a definitive agreement for a stock-for-stock merger. With the deal, Bard would add Woburn, Massachusetts-based MedChem Products' lines of hemostasis, wound closure, and IV drug therapy catheter devices to its product portfolio.